Perception of sleep: Subjective versus objective sleep parameters in patients with Parkinson’s disease in comparison with healthy elderly controls

Happe, Svenja; Klösch, Gerhard; Lorenzo, José Luis López; Kunz, Dieter; Penzel, Thomas; Röschke, Joachim; Himanen, Sari-Leena; Gruber, Georg; Zeitlhofer, J.

doi:10.1007/s00415-005-0785-0

Cited by 39 publications

(48 citation statements)

References 35 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Motor dysfunction was not improved by the use of melatonin [Medeiros et al 2007]. Although undetected differences in motor scores and PSG findings may have been due to the small sample size and a type II error, it must be noted that a significant divergence between PSG and subjective sleep evaluation had been reported in PD patients [Happe et al 2005]. The findings that subjective more than objective findings of impaired sleep quality have a greater negative impact on life quality [Means et al 2003] further suggest that PSG procedures may not be the best method for evaluating sleep disturbance in PD.…”

Section: Melatonin As a Therapeutic Agent In Parkinson's Diseasementioning

confidence: 89%

Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection

Srinivasan¹,

Cardinali

Srinivasan

et al. 2011

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT 1 and MT 2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed.

show abstract

Section: Melatonin As a Therapeutic Agent In Parkinson's Diseasementioning

confidence: 89%

Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection

Srinivasan¹,

Cardinali

Srinivasan

et al. 2011

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

“…The scoring of PSG in patients with IPD is a demanding task, as disease-inherent sleep fragmentation, abrupt sleep-wakefulness transitions, and further electroencephalographic abnormalities may occur. [42][43][44][45][46] However, in the current study automatic pattern recognition had always to be confirmed by manual scoring, based on the long experience of this sleep laboratory in patients with IPD. 47 In addition to reduced REM density, there may also be reduced mean amplitude of the eye movements in patients with IPD.…”

Section: Discussionmentioning

confidence: 99%

Reduced Rapid Eye Movement Density in Parkinson Disease: A Polysomnography-Based Case-Control Study

Schroeder

Rufra

Sauvageot

et al. 2016

Sleep

View full text Add to dashboard Cite

Study Objectives: To explore rapid eye movement density (RD) in patients with idiopathic Parkinson disease (IPD) and to investigate its usefulness as surrogate marker of excessive daytime sleepiness, a frequent complaint in IPD patients. Methods: Retrospective polysomnography study on 81 subjects without dementia: 29 patients with early stage IPD (disease duration ≤ 3 y), 21 patients with middle-stage IPD (disease duration > 3 and < 8 y) and 31 healthy controls (HC). Rapid eye movement (REM) sleep was defined as any REM episode with > 3 min of continuous REM sleep. RD was defined as number of ocular movements per minute of REM sleep. Patients with early stage IPD and HC fulfilled the PDspecific sleepiness questionnaires Parkinson's Disease Sleep Scale (PDSS) and the Nonmotor Symptoms Questionnaire for Parkinson's disease (NMSQuest). Results: RD was lower in patients with IPD than in HC. The difference was most significant between patients with middle stage IPD and HC (P = 0.001), and most prominent for the third REM episode, again when comparing patients with middle stage IPD and HC (P = 0.03). RD was independent from sex, age, and other sleep parameters. In early stage IPD, RD correlated with the PDSS score (r = −0.63, P = 0.001) and the sleep-related questions of the NMSQuest score (r = 0.48, P = 0.017). Conclusions: REM density is reduced in patients with IPD and correlates with subjective scores on sleep impairment. As an indicator of persistent high sleep pressure, reduced RD in IPD is eligible as a biomarker of excessive daytime sleepiness in IPD. It possibly reflects direct involvement of the brainstem REM generation sites by the disease process. RD is a promising new tool for sleep research in IPD.

show abstract

“…3,4,[9][10][11] The percentage represents the difference between average subjective and objective total sleep time (TST). …”

Section: Methodsmentioning

confidence: 99%

“…4 Sleep misperception is most often experienced as wakefulness when the patient has been sleeping, but it can also be experienced as sleeping when the patient has been awake, the latter, with rare exception, in patients without neurological illnesses. [5][6][7][8] To date, there has been no report of sleep perception in multiple sclerosis (MS) patients.…”

Section: Introductionmentioning

confidence: 99%

Disturbances of sleep perception in a group of multiple sclerosis patients: A case report

Attarian

Applebee

Schuman

2010

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Sleep misperception, whether severe enough to qualify as paradoxical insomnia or not, is common in a number of neurological and psychiatric conditions. The objective was to assess sleep perception in a group of multiple sclerosis (MS) patients. As part of an Institutional Review Board (IRB) approved trial designed to assess the efficacy of eszopiclone versus placebo in improving MS patients’ sleep continuity, we observed a pattern of both paradoxical and reverse paradoxical insomnia in a small number of participants. Eight participants (26.7%) had some degree of misperception at some point during the study. Six (20%) had reverse paradoxical insomnia and two (6.7%) had paradoxical insomnia. This is a preliminary observation that we hope will increase awareness of the condition of misperception of sleep in subjects with MS. (Clin. Exp. Neuroimmunol. doi: 10.1111/j.1759‐1961.2010.00012.x, 2010)

show abstract

Perception of sleep: Subjective versus objective sleep parameters in patients with Parkinson’s disease in comparison with healthy elderly controls

Cited by 39 publications

References 35 publications

Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection

Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection

Reduced Rapid Eye Movement Density in Parkinson Disease: A Polysomnography-Based Case-Control Study

Disturbances of sleep perception in a group of multiple sclerosis patients: A case report

Contact Info

Product

Resources

About